1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,840 | 3,880 | 11.04. | |
| 3,780 | 3,940 | 10.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.03. | Singapore Facility powers Cytek's Asia-Pacific expansion | 1 | Singapore Business Review | ||
| 09.03. | Cytek Biosciences, Inc.: Cytek Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact | 1 | GlobeNewswire (USA) | ||
| 04.03. | Cytek Biosciences auf der TD Cowen Gesundheitskonferenz: Einblicke in die strategische Wachstumsplanung | 2 | Investing.com Deutsch | ||
| 27.02. | Cytek Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.02. | Cytek Biosciences outlines $205M-$212M 2026 revenue target amid record Q4 and growth in recurring revenue | 2 | Seeking Alpha | ||
| 26.02. | Cytek Biosciences: Rekordumsatz im vierten Quartal, Gewinnziel jedoch deutlich verfehlt | 1 | Investing.com Deutsch | ||
| 26.02. | Cytek Biosciences GAAP EPS of -$0.34 misses by $0.30, revenue of $62.1M beats by $3.3M | 1 | Seeking Alpha | ||
| 26.02. | Cytek Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| CYTEK BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 26.02. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.02. | Cytek Biosciences, Inc.: Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | 1 | GlobeNewswire (USA) | ||
| 13.01. | Cytek Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.01. | Cytek Biosciences Preliminary Q4 Revenue Up 8% | 1 | RTTNews | ||
| 12.01. | Cytek Biosciences, Inc.: Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results | 140 | GlobeNewswire (Europe) | FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the... ► Artikel lesen | |
| 12.11.25 | Cytek Biosciences, Inc.: TIME Recognizes Cytek Biosciences as One of America's Growth Leaders of 2026 | 5 | GlobeNewswire (USA) | ||
| 06.11.25 | Cytek Biosciences, Inc.: Cytek Muse Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year | 4 | GlobeNewswire (USA) | ||
| 06.11.25 | Cytek reaffirms $196M-$205M 2025 revenue outlook as recurring businesses accelerate | 3 | Seeking Alpha | ||
| 05.11.25 | Cytek Biosciences GAAP EPS of -$0.04 beats by $0.01, revenue of $52.3M beats by $1.16M | 5 | Seeking Alpha | ||
| 05.11.25 | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 29.10.25 | Cytek Biosciences, Inc.: Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry | 1.250 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc.... ► Artikel lesen | |
| 22.10.25 | Cytek Biosciences, Inc.: Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025 | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech, Newron und Emyria: Biotech-Unternehmen rücken in den Fokus einer neuen Substanzdebatte | ||
| MEDIGENE | 0,025 | -18,83 % | Medigene: Zurückziehung - 18.11.2025 | ||
| STRYKER | 289,50 | +0,10 % | Stryker confident of 2026 outlook despite Q1 impact from cyberattack | ||
| BIOFRONTERA | 2,610 | +2,35 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| OCUGEN | 1,524 | +1,74 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| CLINUVEL | 5,504 | -1,18 % | Original-Research: CLINUVEL Pharmaceuticals Limited (von Parmantier & Cie. GmbH): Buy | Original-Research: CLINUVEL Pharmaceuticals Limited - from Parmantier & Cie. GmbH
26.03.2026 / 12:45 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| EDITAS MEDICINE | 2,430 | -3,19 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| GERON | 1,482 | +3,78 % | Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Achieved $48 million and $184 million in RYTELO (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,570 | +0,85 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery... ► Artikel lesen | |
| ASEP MEDICAL | 0,153 | +0,66 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,750 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates | On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 28,310 | +2,91 % | Celldex closes $345 million stock offering | ||
| MYRIAD GENETICS | 3,773 | +1,84 % | Myriad Genetics, Inc.: Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting | ||
| CARDIFF ONCOLOGY | 1,409 | +4,91 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| ALDEYRA | 1,520 | 0,00 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen |
Das Unternehmen CYTEK BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,03 % bei einem Aktienkurs von 3,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTEK BIOSCIENCES INC finden Sie auf Wallstreet Online.